Development of antinuclear antibodies during acebutolol therapy.
Eleven patients were studied while taking the beta blocker acebutolol for a period ranging from 12 to more than 24 wk. Control titers for fluorescent antinuclear antibody (ANA) were obtained in all. Serial testing was performed over the duration of the therapy and following its discontinuation. Additional immunologic testing was performed in most patients. The patients were observed closely for the development of clinical autoimmune disease. Using a sensitive assay, fluorescent ANA developed in 8 of 9 patients with negative values in the control period. In no patient has evidence of clinical autoimmune disease developed. In general, the titers of ANA tended to rise with increasing duration of therapy and decline after its discontinuation. Positive lupus erythematosus cell preparations were also observed in several patients. These data suggest that autoantibodies are frequently induced by acebutolol and, although no evidence of clinical autoimmune disease has been reported, immunologic surveillance is warranted.
D000070:Acebutolol / Q000009:adverse effects*; D000328:Adult; D000906:Antibodies / Q000378:metabolism; D000974:Antibodies, Antinuclear / Q000378:metabolism*; D004247:DNA / Q000276:immunology; D005128:Eye Diseases / Q000139:chemically induced; D005260:Female; D005455:Fluorescent Antibody Technique; D006801:Humans; D008297:Male; D008875:Middle Aged; D009504:Neutrophils
D000906:Antibodies; D000974:Antibodies, Antinuclear; D000070:Acebutolol; D004247:DNA